Panobacumab

Panobacumab (proposed INN) is a monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.

[1] It is a fully human pentameric IgM antibody with a mouse J chain.

[1] Panobacumab is being developed by Aridis Pharmaceuticals.

As of November 15th it is in phase 2 clinical trials.

You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.

Panobacumab molecule consisting of five base units.
1: Base unit.
2: Heavy chains .
3: Light chains .
4: J chain .
5: Intermolecular disulfide bonds .